XORTX finishes making trial batches of oxypurinol gout tablet, turns to regulators
The Canadian drugmaker has produced and packed the study material for XORLO, its gout candidate, clearing a practical hurdle before it seeks permission to dose patients.
XORTX Therapeutics said on 16 November 2026 that the drug supply for its XRX-OXY-102 study of XORLO, an oxypurinol tablet for gout, has been made and packaged. Having the material in hand removes a manufacturing dependency before the study can go ahead, though the company has not yet said when patients will be dosed.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): XORTX Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.